Travoprost in the Treatment of Ocular HypertensionTravoprost in the Treatment of Ocular Hypertension

What is the most effective dosing strategy of travoprost for the treatment of ocular hypertension? This new study compares daily vs alternate day use. Journal of Glaucoma
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Related Links:

Conditions:   Glaucoma;   Ocular Hypertension;   Filtering Surgery Interventions:   Procedure: phacotrabeculectomy;   Procedure: ExPress antiglaucoma surgery combined with phacoemulsification Sponsor:   Medical University of Bialystok Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Machen L, Razeghinejad R, Myers JS Abstract Introduction: Fixed-combination glaucoma medications have altered the paradigm of ocular hypertension and glaucoma treatment and are in widespread use today. A comprehensive review of fixed-combination medications will help educate and inform providers for optimal patient care.Areas covered: In this review, the authors describe the composition, mechanism of action, efficacy, side effects, and safety profile of fixed-combination agents for the treatment of ocular hypertension and glaucoma as well as comparisons between the most frequently prescribed medications.Ex...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
We examined the conversion rates of OHT to primary open-angle glaucoma (POAG) in England and assessed factors associated with risk of conversion. METHODS: Electronic medical records of 45 309 patients from five regionally different glaucoma clinics in England were retrospectively examined. Conversion to POAG from OHT was defined by deterioration in visual field (two consecutive tests classified as stage 1 or worse as per the glaucoma staging system 2). Cox proportional hazards models were used to examine factors (age, sex, treatment status and baseline intraocular pressure (IOP)) associated with conversion. ...
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Br J Ophthalmol Source Type: research
AbstractIntroductionNew open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed. Netarsudil, a novel Rho kinase inhibitor approved by the US Food and Drug Administration, reduces intraocular pressure (IOP) by increasing trabecular outflow. Two phase  3 superiority studies compared a fixed-dose combination (FDC) of netarsudil and the prostaglandin latanoprost with each active component for IOP-lowering efficacy.MethodsPooled efficacy and safety data were analyzed from MERCURY-1 and -2 studies in patients with O...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
ABSTRACT Purpose: To investigate the relationships between (i) thickness of the retinal nerve fiber layer, optic nerve head topography, and visual field parameters and (ii) corneal biomechanical properties in normal controls and patients with ocular hypertension and primary open-angle glaucoma. Methods: This observational, cross-sectional study included 68 eyes with primary open-angle glaucoma, 99 eyes with ocular hypertension and 133 control eyes. Corneal biomechanical properties, optic nerve head topographic features, retinal nerve fiber layer thickness, and visual fields were assessed in all cases. Corneal biomechanical...
Source: Arquivos Brasileiros de Oftalmologia - Category: Opthalmology Source Type: research
Conclusions: Glaucoma after graft surgery is a well-known and devastating complication, and as numbers of graft surgery performed increases, so will the incidence of glaucoma. MIGS devices such as the Xen45 Gel Stent (Allergan plc) should become a part of our accepted armory to treat raised IOP refractory to medical treatment without delay.
Source: Cornea - Category: Opthalmology Tags: Clinical Science Source Type: research
Bimatoprost implant (Durysta) delivers 10 µ g of the prostaglandin analog and is an alternative to daily topical eye drops in patients with open-angle glaucoma or ocular hypertension.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Ophthalmology News Alert Source Type: news
DUBLIN, March 5, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
CONCLUSION: In post-trabeculectomy Asian eyes with well-controlled IOP, higher long-term IOP fluctuation may be associated with greater VF progression. PMID: 32139502 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Br J Ophthalmol Source Type: research
CONCLUSIONS: The Cardiff Model of Glaucoma Care offers novel clinical and adherence insights at marginal costs while acceptable to patients. Healthcare professionals felt that 4 hour and 4 week follow-up appointments could cause administrative problems. A streamlined version of the pathway has therefore been developed to facilitate clinical adoption. TRIAL REGISTRATION NUMBER: ISRCTNID:ISRCTN75888393. PMID: 32139500 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Br J Ophthalmol Source Type: research
More News: Glaucoma | Health | Hypertension | Opthalmology | Study | Travatan